Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of acyclovir pharmaceutical composition

A composition and drug technology, used in drug delivery, active ingredients of heterocyclic compounds, pharmaceutical formulations, etc., can solve the problems of large dosage of sustained-release materials, sudden drug release, poor release consistency, etc. Stable and less adverse effects

Active Publication Date: 2017-08-08
KAMP PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above-mentioned patented process adopts ordinary wet granulation, and the amount of sustained-release materials is relatively large; the release consistency is poor, which may easily cause sudden or uneven drug release

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of acyclovir pharmaceutical composition
  • A kind of acyclovir pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Acyclovir 44%

[0031] Ethyl Cellulose 30%

[0032] Sodium chloride 2%

[0033] Lactose 13%

[0034] Tragacanth Gum 10%

[0035] Talc 1%

Embodiment 2

[0037] Aciclovir 40%

[0038] Ethylcellulose 31%

[0039] Sodium chloride 2%

[0040] Lactose 13%

[0041] Tragacanth Gum 12%

[0042] Talc 1%

Embodiment 3

[0044] Aciclovir 45%

[0045] Ethylcellulose 27%

[0046] Sodium chloride 3%

[0047] Lactose 10%

[0048] Tragacanth Gum 13%

[0049] Talc 2%

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine preparation, in particular to an acyclovir pharmaceutical composition and a preparation method thereof. The existing technology adopts ordinary wet granulation, and the amount of sustained-release material is relatively large; the release consistency is poor, and it is easy to cause sudden or uneven release of the drug. The present invention provides a drug with higher drug release stability and drug safety Acyclovir sustained-release tablet, the technical scheme adopted in the present invention is a kind of acyclovir pharmaceutical composition, comprises the mixture that is made up of acyclovir, framework material, electrolyte, carbohydrate, hydrophilic gel, lubricant . The sustained-release rate of the present invention is stable, and is a first-order speed process, which can overcome the "peak and valley" phenomenon produced after multi-dose administration of general preparations, reduce the frequency of medication, greatly reduce the stimulation to the gastrointestinal tract, and have few adverse reactions.

Description

technical field [0001] The invention relates to the field of pharmaceutical production, in particular to an acyclovir pharmaceutical composition and a preparation method thereof. Background technique [0002] Acyclovir, also known as acyclovir (ACV for short), is a nucleoside antiviral drug with a chemical name of 9-(2-hydroxyethoxymethyl)guanine. In 1981, Wellcome Company first listed this product in the UK, trade name: Zovirax. In 1982, the FDA approved this product to be marketed in the United States. At present, aciclovir is one of the main medicines sold worldwide. Acyclovir is the homotype of acyclic deoxyguanosine, which is a component of DNA. Acyclovir is similar in structure, except that the cyclic sugar structure is replaced by an acyclic side chain. It is mainly used for various infections caused by herpes simplex virus, and can be used for initial or recurrent skin, mucous membrane, external genital infection and HSV infection in immunocompromised persons. It...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/22A61K31/522A61K47/38A61K47/34A61K47/32A61P31/22
Inventor 曾培安吴健民张浩贺莲
Owner KAMP PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products